NasdaqGM - Delayed Quote USD

Drugs Made In America Acquisition Corp. Units (DMAAU)

10.17

-0.01

(-0.10%)

As of April 25 at 4:00:00 PM EDT. Market Open.

Drugs Made in America Acquisition Corp. Announces Advisory Team

Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactivel

GlobeNewswire 2 months ago

DMAAU
-0.10%
Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025

Fort Lauderdale, Florida, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that, commencing February 25, 2025, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and rights included in the units. No fractional rights will be issued upon separation of the units and only whole rights will trade. The ordinary shares and rights that are separated will t

GlobeNewswire 2 months ago

DMAAU
-0.10%
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option

Fort Lauderdale, Florida, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) today announced that the underwriter of its previously announced initial public offering fully exercised its option to purchase an additional 3,000,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $30,000,000. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “DMAAU” on January

GlobeNewswire 2 months ago

DMAAU
-0.10%
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market ("Nasdaq") under the ticker symbol "DMAAU” on January 28, 2025. Each unit consists of one ord

GlobeNewswire 2 months ago

DMAAU
-0.10%

Performance Overview

Return	DMAAU	S&P 500 (^GSPC)
YTD	+1.60%	-5.64%
1-Year	+1.60%	+8.82%
3-Year	+1.60%	+29.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Drugs Made In America Acquisition Corp. Units (DMAAU)

Drugs Made in America Acquisition Corp. Announces Advisory Team

Drugs Made In America Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing February 25, 2025

Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option

Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

Performance Overview